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Abstract
The Friend virus SFFV (Spleen Focus Forming Virus) provokes an acute erythroblastosis in
susceptible strains of mice that progresses to overt erythroleukemia by a multi-step process. For
virologists, the Friend virus-induced disease has provided deep insights into the host mechanisms
influencing susceptibility to retroviral infection and viremia. These insights have contributed to the
understanding of HIV and other human retroviral infections. For cell biologists and oncologists, this
leukemia has been a powerful experimental model to identify critical oncogenes involved in a multi-
stage process, to understand the contribution of host genes to cancer development, and to
investigate the mechanisms leading to cell growth autonomy. This model also provided an example
of oncogenic reversion since Friend tumor cells can reinitiate their erythroid differentiation
program when exposed in vitro to some chemical inducers. This review highlights recent findings
demonstrating that the leukemic progression depends on the cooperation of at least two
oncogenic events, one interfering with differentiation and one conferring a proliferative advantage.
The Friend model of leukemia progression recapitulates the two phases of human acute myeloid
leukemia (AML). Coupling of insights from studies on the Friend erythroleukemia with knowledge
on AML might allow a better understanding of the molecular mechanisms involved in the evolution
of leukemia in mice and men.
Review
Friend retroviruses and Friend disease have provided pow-
erful experimental tools in the fields of virology and
oncology. During the nineteen-seventies, they have been
of great importance in understanding the mechanisms of
resistance of mice to retroviral infection, leading to the
identification of several host genes that affect Friend virus
replication in target cells and control host immune
response to the viral antigens [1,2]. Recent advances made
in primates retroviral restriction activities have given
major relevance to the previously accrued murine
data[3,4]. For example, the retroviral restriction factor Fv1
(Friend virus susceptibility factor 1) [5-8] provides resist-
ance to infection by particular murine leukemia viruses,
and the Ref1/Lv1/TRIM5 factor mediates resistance to
diverse retroviruses in primates, including humans [9-11].
These mechanisms of resistance target a common capsid
molecular determinant [12,13]. Remarkably, the murine
gene Rfv3 (Recovery from Friend virus 3) which influences
Friend viremia [14] and retroviral neutralizing antibody
responses [15] encodes APOBEC3 known otherwise as a
powerful antiretroviral factor that restricts retroviral viri-
ons of cognate origin [16-19]. Moreover, the erythro-
leukemia induced in mice by Friend retroviruses represent
experimental neoplasms that have been valuable for char-
acterizing the multi-stage progression of leukemia, for
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identifying oncogenes or tumor suppressor genes
involved during this process, for understanding the con-
tribution of host genes to cancer, and for investigating the
mechanisms leading to cell growth autonomy. The pur-
pose of this review is to highlight the important insights
that have arisen from the studies on the Friend disease
and to discuss the molecular events involved in the out-
growth of preleukemic cells and their progression to
malignancy.
Friend diseases
Friend acute erythroleukemias are caused in susceptible
mice by various strains of Friend leukemia viruses (FLV).
The description of the initial isolate took place 50 years
ago when the American virologist Charlotte Friend
observed that newborn mice inoculated with Ehrlich
murine carcinoma cells developed an acute erythroblasto-
sis that could be subsequently transmitted by cell-free
extracts prepared from the spleens of diseased mice [20].
The early description of the disease indicated that the orig-
inal isolate (termed anemia-inducing Friend virus or FLV-
A) caused an anemia mainly due to hemodilution [21].
Since the original report by C. Friend, a number of other
isolates capable of inducing a disease spectrum compara-
ble to FLV-A have been identified. Among these, the
Rauscher isolate was biologically similar to FLV-A [22]. A
few years later, derivatives were obtained. In contrast to
FLV-A causing an anemia, the derivatives increased the
levels of erythrocytes in the peripheral blood (poly-
cythemia) and was termed polycythemia-inducing Friend
virus or FLV-P [23]. Adult or newborn mice inoculated
with either FLV-A or FLV-P develop a disease with no
latency. Both virus isolates induce an erythroblastosis that
rapidly progresses to acute transformation (Figure 1). The
early stage is characterized by a rapid increase in the
number of proerythroblastic cells leading to massive
hepatosplenomegaly that may be fatal by accidental
spleen rupture. These proerythroblasts die in situ or differ-
entiate into abnormal erythrocytes either in the absence of
erythropoietin (Epo), in the case of FLV-P, or with a
hypersensitivity to Epo, in the case of FLV-A[24-27]. The
target cell in which both FLV-P and FLV-A express their
pathogenic effect is an Epo-responsive progenitor cell that
was identified as a late BFU-E or a CFU-E [25,27,28].
Although Friend virus-infected erythroid progenitors dra-
matically increase in number, they retain limited prolifer-
ation capacity and are not tumorigenic in vivo. Within two
to three weeks after virus inoculation, a clonal population
of proerythroblastic cells blocked in their differentiation
program first emerges in the spleen and then invades the
animal [29-31]. These leukemic cells have extensive pro-
liferative capacity, the ability to be serially transplantable
in vivo, and the capacity to eventually establish permanent
cell lines in vitro. Cell lines established in culture were
called Friend tumor cells. Of note, the erythroid differen-
tiation program can be reinitiated in Friend tumor cells
when exposed in vitro to some chemical inducers like
dimethyl sulfoxyde, hexamethylene bisacetamide, butyric
acid or hemin [32]. This contrasts importantly with B-
lymphocyte or T-lymphocyte transformation by Bovine
Leukemia Virus (BLV) or Human T-cell Leukemia Virus
(HTLV)[33] which are phenotypically irreversible. Thus,
the Friend tumor cells have provided a useful in vitro
model for studying the molecular processes of erythroid
terminal differentiation.
Friend viruses
Both FLV-A and FLV-P isolates contain at least two viral
components: a replication-competent Friend murine
leukemia virus (F-MuLV) and a replication-defective
spleen focus forming virus (SFFV). F-MuLV behaves as a
helper supplying the replication-defective functions to
SFFV, while SFFV is the pathogenic component responsi-
ble for the acute erythroblastosis. SFFV is responsible for
the state of either polycythemia (SFFVP) or anemia
(SFFVA). Further studies have demonstrated that the
Rauscher SFFV (Ra-SFFV) was genetically equivalent to the
Friend SFFVA[34,35]. The conclusive proof that SFFV was
the pathogenic component responsible for the acute
erythroblastosis was that F-MuLV-free viral preparations
containing only the SFFV genome could provoke an eryth-
roid proliferative disease when inoculated in mice [36].
The role of gp55 in erythroblastosis
The SFFV genome differs from the genome of other
acutely oncogenic retroviruses in that it does not contain
oncogenic sequences derived from a cellular proto-onco-
gene. This property is similar to that observed for HTLV-
1[37,38]. The pathogenicity of SFFV stems from the prod-
uct of its env  gene that encodes a glycoprotein with a
molecular mass of 55 kDa (gp55P and gp55A) [39,40]. The
env gene contains ecotropic env sequences derived from F-
MuLV and dual-tropic sequences probably acquired by
genetic recombination with env sequences from an endog-
enous polytropic virus present as multiple copies in the
mouse genome [41]. Thus, gp55 presents structural ele-
ments homologous to polytropic env glycoproteins in its
amino-terminal region and elements homologous to the
ecotropic MuLV env gp70 in its carboxy-terminal part. The
gp55 contains an extracellular domain, a transmembrane
domain and a short cytoplasmic tail [42]. Gp55 is not
processed in the viral particle but remains in the mem-
branes of the infected cells. A small fraction of gp55
(3–5%) is highly glycosylated in a gp65 form found
anchored at the cell surface, while the majority of gp55
remains in the rough endoplasmic reticulum [34]. This
glycosylation processing is required for the SFFV leuke-
mogenic activity [43].Retrovirology 2008, 5:99 http://www.retrovirology.com/content/5/1/99
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To decipher the exact role of gp55 in the Friend disease,
various models have been elaborated. A retroviral vector
transducing only the gene encoding gp55P  was con-
structed. Upon inoculation in mice, it induced the early
stage of the Friend disease similarly to that achieved with
the entire SFFVP genome [44]. Another study used trans-
genesis. The gp55P-transgenic mice developed a poly-
cythemia associated with a massive proliferation of
erythroid precursor cells that were not transplantable
[45]. Thus, these elegant approaches provided convincing
evidence that gp55 is directly responsible for the early
erythroblastosis.
An important insight into the gp55 function in erythroid
precursor cells was the demonstration that gp55 directly
interacts with the receptor for erythropoietin (EpoR) [46].
This interaction occurs through the respective transmem-
brane domains of EpoR and gp55. The binding of gp55 to
EpoR, that is highly expressed at the transition of late
BFU-E to CFU-E, results in EpoR activation and promotes
the Epo-independent proliferation and differentiation of
erythroid progenitor cells [42,43,47,48]. Rare amino acid
differences have been identified in the transmembrane
domains of gp55P and gp55A. Due to these differences, the
level of EpoR activation remains incomplete with gp55A
explaining the increase in Epo sensitivity [49] but not
autonomy from Epo. In addition to EpoR, gp55 also
recruits the short form of the stem-cell-kinase receptor (sf-
Stk) as a signaling partner [50,51]. Stk/RON is a tyrosine
kinase receptor of the Met family. sf-Stk retains the trans-
membrane and the tyrosine kinase domains, but lacks the
extracellular ligand binding domain of Stk [51-53]. Stk/
RON is encoded by the Fv2 gene (Friend virus susceptibil-
ity gene 2) [52], previously known as a gene determining
Friend erythroleukemia is a two-step disease Figure 1
Friend erythroleukemia is a two-step disease. The target cell for SFFV is a late BFU-E or a CFU-E. SFFV infection induces 
the proliferation of proerythroblastic cells that differentiate into erythrocytes in the absence of Epo, in the case of FLV-P infec-
tion. The second step is characterized by the outgrowth of Friend tumor cells that can be serially transplanted into mice and 
cultured as permanent cell lines without growth factor. The tumor cells are blocked in differentiation, but can be induced to 
differentiate along the erythroid pathway by chemical inducers. A pellet of red blood cells derived from a Friend tumor cell line 
treated for 5 days with DMSO is shown in the box.
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the susceptibility of some strains of mice (Fv2s/s) to the
Friend disease [54,55]. Transcription of sf-Stk is naturally
initiated from an internal promoter within the Stk gene,
and this internal promoter is deleted in mice resistant to
Friend virus (Fv2r/r) [52]. Strikingly, the pathology that
developed in gp55P-transgenic mice was not observed
under the genetic Fv2r/r background [45], emphasizing the
essential role of sf-Stk in gp55-mediated erythroid prolif-
eration. In SFFV-infected mice, gp55, EpoR and sf-Stk are
effectors in signaling pathways which encompass the sig-
nal transducers and transcriptional activators STATs
[56,57], PI3-kinase/AKT [50], the molecular adaptors
Grb2/Gab2 [58], the Lyn kinase [59], the p38MAP kinase
[60], and the ERK1/2 MAP kinases [61,62]. Constitutive
activation of these signaling pathways by the gp55/EpoR
and gp55/sf-Stk complexes leads to the dysregulation of
proliferation, survival and differentiation of SFFVP-
infected erythroid progenitors in Fv2s/s mice which result
in acute erythroblastosis.
The oncogenic events during Friend erythroleukemia
Although SFFV is an acutely transforming retrovirus, it
induces malignant transformation of erythroid cells by a
mechanism of insertional mutagenesis which is usually
employed by non-acute leukemogenic virus. Identifica-
tion of SFFV proviruses integration sites in the genome of
various Friend tumor cells was the first molecular proof
for the clonal nature of the leukemic transformation [63].
The molecular characterization of the SFFV integration
sites revealed that SFFVP or SFFVA preferentially integrates
at the same genomic locus in 95% of the Friend tumor
cells, called spi-1  for SFFV proviral integration site-1
[64,65]. The spi-1 locus is transcriptionally activated by
the transcriptional enhancers present in the SFFV LTR
[66,67], producing the overexpression of a normal spi-1
mRNA translated into a normal Spi-1 protein [66,68].
During DMSO-induced erythroid differentiation of
Friend tumor cells, it was noticed that one of the early
events was a marked decline in the level of Spi-1 expres-
sion [69]. Based on this observation, it was proposed that
the arrest in erythroid differentiation was, at least in part,
due to Spi-1 overexpression. The high recurrence of Spi-1
insertional mutation in Friend tumor cells suggested that
Spi-1 overexpression was cooperative with the constitu-
tive signaling from gp55/EpoR and sf-Stk/EpoR com-
plexes to induce the malignant transformation of the
proerythroblast. Indeed, in a heterologous avian model of
erythroid self-renewal and differentiation, the effects of
Spi-1 on proliferation, survival and differentiation arrest
required the co-expression of Spi-1 with an EpoR activated
either by gp55 or by a mutation on the residue R129C,
which mimics EpoR/gp55 activation [70-72].
Besides Spi-1 overexpression, recurrent alterations in the
tumor suppressor p53 gene were also detected in the late
stage of the Friend disease. Allelic deletions or missense
mutations led to loss of p53 tumor suppressive function
[73-75], and it was shown that Friend leukemia develop
more rapidly in transgenic mice expressing a mutant p53
allele, or in p53-null mice, than in normal mice [76,77].
Although the ectopic expression of a normal p53 protein
in Friend tumor cells induces apoptosis and hemoglobin
production [78], the loss or the mutation of p53 seems to
favor the growth and survival of leukemic proerythrob-
lasts rather than specifically altering erythroid differentia-
tion.
The role of Spi-1 in the arrest of erythroid differentiation
To specify the role of Spi-1 in erythroleukemia, a murine
model of spi-1 transgenesis has been constructed [79]. The
spi-1 transgene, placed under the control of the SFFVP LTR,
was introduced into the germinal lineage of Fv2s/s mice.
Spi-1 transgenic mice develop, within 3 to 4 months after
birth, a severe anemia and a massive swelling of the spleen
followed by an enlargement of the liver. Bone marrow,
spleen, and liver are infiltrated by proerythroblasts
arrested in differentiation, mostly at the basophilic stage.
These proerythroblastic cells can be established in vitro as
permanent cell lines that are exquisitely dependent on
Epo for proliferation and survival, and the cells are unable
to induce tumors when engrafted in vivo. The Epo depend-
ency was confirmed in vivo by the demonstration that ele-
vation of hematocrit levels (above 60%) by repeated red
blood cells transfusions caused regression of the hepat-
osplenomegaly and disappearance of circulating blasts.
Nonetheless, in the animal, erythroblasts expansion
occurs in both the presence of Epo in the plasma and the
secretion of SCF (stem cell factor) in the marrow or spleen
microenvironment. In fact, SCF cooperates with Epo to
maintain the in vitro survival and proliferation of the spi-1
transgenic proerythroblasts when Epo is used at limiting
concentrations [80]. Thus, the spi-1  transgenic model
demonstrates that an ectopic expression of Spi-1 results in
a block in the maturation program of erythroid precursor
cells without removing their growth factor requirement
for survival.
The function of Spi-1 in the erythroid differentiation
blockage is multifaceted. The extinction of Spi-1 by spi-1-
interfering RNAs in spi-1  transgenic proerythroblasts is
sufficient to reinstate the erythroid differentiation pro-
gram [81]. This differentiation process is associated with
an arrest in proliferation due to both cell death by apop-
tosis and cell cycle arrest. The mechanisms controlled by
Spi-1 that permit survival of the proerythroblast and avoid
an exit from the cell cycle are still subjected to speculation.
Spi-1 is identical to the transcription factor PU.1, a mem-
ber of the ETS family. Studies with PU.1 knock-out mice
have shown that PU.1 supports hematopoiesis at different
stages. Deficiency in PU.1 results in the selective loss of BRetrovirology 2008, 5:99 http://www.retrovirology.com/content/5/1/99
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lymphoid and macrophage development, and a delayed
development of neutrophils and T cells [82-86]. In addi-
tion, PU.1 plays a role in regulating the commitment of
multipotent hematopoietic progenitors [87,88]. Spi-1/
PU.1 functions require the ability of the protein to bind
purine-rich DNA sequences in the promoters and enhanc-
ers of target genes [68,89]. Distinct threshold levels of
PU.1 also determine function, with high levels driving
precursors to a myeloid cell fate, while moderate levels
specify B lymphoid development [90]. Notably, Spi-1/
PU.1 down-regulation is required for normal erythroid
development [91,92]. Thus, Spi-1 overexpression in the
proerythroblast probably changes the delicate balance of
transcriptional activities required for normal erythropoie-
sis.
It was postulated that excess Spi-1 may disrupt the func-
tion of an erythroid factor and, in this hypothesis, GATA-
1 was an obvious candidate [93-95]. Indeed, GATA-1-defi-
cient erythroid cells fail to mature beyond the proeryth-
roblast stage and die by apoptosis [96,97]. Several studies
have reported a reciprocal inhibition of Spi-1/PU.1 and
GATA-1 functions through direct interaction [98-101].
Furthermore, the concept that Spi-1 could inhibit the
function of GATA-1 in erythroleukemic cells is supported
by the reversal of tumorigenicity and the re-initiation of a
differentiation program when GATA-1 expression is
ectopically imposed in a Friend tumor cell line [102].
Nonetheless, target genes for GATA-1, such as EKLF, NF-
E2, β globin, EpoR and GATA-1-itself are expressed in
both Friend and spi-1 transgenic cells [79](our unpub-
lished data) indicating that some GATA-1 functions are
not abolished by Spi-1 overexpression. Global transcrip-
tome analyses of preleukemic spi-1 transgenic proeryth-
roblasts should provide data allowing the elucidation of
the direct targets downstream Spi-1 and the molecular
pathways leading to erythroleukemogenesis. As a first
indication, transcription of the fli-1 gene is directly regu-
lated by Spi-1 in Friend tumor cells [103]. Fli-1 is a tran-
scription factor of the ETS family that behaves as an
oncogene when activated by insertional mutagenesis in
late erythroid tumors induced by the Friend MuLV alone
[104]. Thus, Fli-1 dysregulation may contribute, in part, to
the erythroid differentiation arrest induced by Spi-1.
Another mechanism may involve the phosphatase SHP-1
[105] that is transcriptionally up regulated by Spi-1 [106].
SHP-1 may interfere with the activation of STAT1 and
STAT3 and inhibit their DNA binding activities, contribut-
ing to the erythroid differentiation arrest[57].
The two-stage erythroleukemia in spi-1 transgenic mice
During disease progression, fully transformed proeryth-
roblastic cells emerge that are characterized by both
autonomous growth in vitro and tumorigenicity in vivo.
Thus, like the disease induced by the Friend virus com-
plex, spi-1 transgenic mice develop a malignant process
that evolves in two steps (Figure 2) whereby the blastic
phase reflects the outgrowth of a malignant erythroblastic
cell subpopulation with acquired genetic lesions. Accord-
ing to the data accumulated with studies on the Friend
disease, abnormalities occurring in the p53  gene were
examined. Inactivating p53 mutations were frequently
observed in malignant spi-1 transgenic proerythroblasts,
and we reported that disease progression was highly accel-
erated in a p53-null background [107]. Nevertheless, Epo-
dependent and non-tumorigenic cells can be isolated dur-
ing the early erythroblastic phase of diseased p53-/--spi-1
transgenic mice indicating that p53 germline deletion is
not sufficient to confer the malignant phenotype in this
context [108]. As for the Friend disease, p53 abnormalities
appear more as a permissive event supporting the illegiti-
mate survival of proerythroblasts harboring genetic aber-
rations than a direct transformation event.
Next, signaling alterations were prospected. These studies
led to the identification of point mutations in the Kit gene
in 86% of tumors isolated late during leukemia progres-
sion [80]. Kit, the tyrosine kinase receptor for SCF, is
expressed on hematopoietic stem cells and committed
progenitor cells of the different blood cell lineages
[109,110]. Kit is activated by SCF binding, which induces
receptor dimerization followed by the activation of the
intrinsic tyrosine kinase and receptor transphosphoryla-
tion on specific tyrosine residues [111,112]. By triggering
multiple signaling pathways including ERK1/2 MAP
kinases, PI3Kinase, and Src kinases, Kit activation modu-
lates cell survival and proliferation [113-115]. Most Kit
mutations found in spi-1 transgenic leukemic cells affect
amino acids located in the Kit catalytic domain (mainly
codon 814 and occasionally codon 818). Of note, similar
mutations were found in human mastocytosis [116,117]
and acute myeloid leukemia [118-120]. These gain-of-
function mutations confer ligand-independent tyrosine
kinase activity to Kit. The mutated forms of Kit constitu-
tively activate MAP kinases and PI3Kinase/AKT pathways
in the spi-1 transgenic leukemic cells [80,121]. When the
expression of Kit mutants is enforced in spi-1 transgenic
preleukemic proerythroblasts, cells become growth-factor
independent and tumorigenic in vivo. Thus, a constitutive
signaling from Kit mutants combined to Spi-1 overexpres-
sion leads to malignant transformation of proerythrob-
lasts (Figure 3).
From murine to human
AML in human are characterized by an uncontrolled
expansion of immature blasts, which fail to differentiate
normally. These leukemias are classified into sub-types
according to the predominance of the altered myeloid lin-
eage. It is currently accepted that the disease progresses
from a chronic phase to an acute blastic crisis. Molecu-Retrovirology 2008, 5:99 http://www.retrovirology.com/content/5/1/99
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larly, leukemias are associated with multiple genetic alter-
ations, including chromosomal translocations and
mutations. Overviews on the genetic alterations found in
AML are detailed in recent reviews [122-127]. One impor-
tant observation is that the genetic alterations can be
divided into two classes. One class targets transcription
factors that play a regulatory role in hematopoietic devel-
opment. These transcription factors are frequently modi-
fied through chromosomal translocations and the
resulting chimeric proteins inhibit differentiation in a par-
ticular hematopoietic cell lineage. For example, the pro-
myelocytic leukemia-retinoic acid receptor α (PML/
RARα) expressed from the t(15;17) translocation is asso-
ciated with 99% of acute promyelocytic leukemia [128].
PML/RARα behaves as a transcriptional repressor for the
hormonal receptor RARα [129]. In the second class, muta-
tions affect signaling effectors like tyrosine kinases [125].
These mutations are gain-of-function and provide prolif-
erative signals, as exemplified by point mutations induc-
ing the constitutive activation of the tyrosine kinase
receptor FLT3 in ~30% of AML [122,130,131]. Strikingly,
murine models designed to express one genetically modi-
fied protein, using the transplantation of retrovirally-
transduced bone marrow cell or transgenesis, showed that
one type of mutation does not induce an acute leukemia
on its own. Generally, they provoke a myeloproliferative
disorder. Progression to leukemia requires either a long
latency, making plausible the occurrence of a second
mutation, or an additional treatment with mutagenic
compounds. The concept emerging from this complexity
is that an acute leukemia arises from the cooperation
between two events: one mutation interfering with differ-
entiation and the other mutation conferring a prolifera-
tion advantage [132].
Erythroleukemia in spi-1 transgenic mice is a two-step disease Figure 2
Erythroleukemia in spi-1 transgenic mice is a two-step disease. The first step occurring in spi-1 transgenic mice is a 
massive proliferation of proerythroblasts, arrested in differentiation around the CFU-E/proerythroblast stage. These cells can 
be established in vitro as Epo-dependent cell lines. In a second step, malignant proerythroblastic cells emerge that proliferate in 
vitro without Epo and are tumorigenic when grafted into Nude mice.
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Both the Friend and spi-1 transgenic models demonstrate
that leukemia development depends on the cooperation
between one mutation that impairs differentiation and a
second mutation that promotes autonomous cell growth
(Figure 1). In that way, these murine models provide
proof-of-principle for the "two-hits" model of leukemo-
genesis [132]. They highlight that complementation
between the two classes of mutations is more important
for leukemogenesis than the timing order of their occur-
rence.
Conclusion
Significant advances have been made in the mechanisms
of leukemia from studies on murine models of erythro-
leukemia. In the nineteen-sixties, these studies established
the concept of multiple-step evolution of leukemia. Forty
years later, these models validate the concept of oncogenic
cooperativity merging the diversity of genetic lesions that
underlie the development of acute myeloid leukemia in
human. A future challenge will be to integrate the net-
works of transcriptional regulation and signaling toward a
better understanding of leukemogenic processes.
Oncogenic cooperation in murine erythroleukemia Figure 3
Oncogenic cooperation in murine erythroleukemia. During Friend acute erythroleukemia, the early expansion of eryth-
roid progenitors is due to the activation of EpoR and sf-STK by the viral gp55. The blastic crisis is associated with the overex-
pression of the transcription factor Spi-1/PU.1, occurring by insertional mutagenesis due to SFFV. During erythroleukemia 
progression in spi-1 transgenic mice, the initial oncogenic event is the overexpression of Spi-1/PU.1 by germinal mutation that 
induces a differentiation arrest of the proerythroblast. The blastic crisis is associated with activating mutations in the Kit gene 
that promote the Epo-independent proliferation and survival of the malignant proerythroblast.
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